Highlights
KLSE: PHARMA (7081)       PHARMANIAGA BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
2.07   0.00 (0.00%)  2.04 - 2.07  42,300
Trade this stock with T+7 trading account. Find out more.

Financials


Market Cap: 541 Million

Market Cap 541 Million
NOSH 261 Million

Latest Audited Result:  31-Dec-2017

Latest Audited Result: 31-Dec-2017
Announcement Date 13-Mar-2018
Next Audited Result: 31-Dec-2018
Est. Ann. Date: 13-Mar-2019
Est. Ann. Due Date: 29-Jun-2019

Latest Quarter:  30-Sep-2019 [#3]

Latest Quarter: 30-Sep-2019 [#3]
Announcement Date 20-Nov-2019
Next Quarter: 31-Dec-2019
Est. Ann. Date: 21-Feb-2020
Est. Ann. Due Date: 29-Feb-2020
QoQ | YoY   -94.82%  |    -96.80%

Annual (Unaudited) ( EPS: 16.26, P/E: 10.05 )

Revenue | NP to SH 2,384,956  |  42,468
RPS | P/RPS 912.97 Cent  |  0.23
EPS | P/E | EY 16.26 Cent  |  10.05  |  9.95%
DPS | DY | Payout % 15.93 Cent  |  9.12%  |  98.01%
NAPS | P/NAPS 1.95  |  1.03
YoY   -21.10%
NP Margin | ROE 1.81%  |  8.33%
F.Y. | Ann. Date 31-Dec-2018  |  21-Feb-2019

T4Q Result ( EPS: 12.94, P/E: 15.99 )

Revenue | NP to SH 2,701,491  |  33,816
RPS | P/RPS 1,034.14 Cent  |  0.20
EPS | P/E | EY 12.94 Cent  |  15.99  |  6.25%
DPS | DY | Payout % 10.47 Cent  |  5.06%  |  80.87%
NAPS | P/NAPS 1.98  |  1.05
QoQ | YoY   -30.11%  |    -43.39%
NP Margin | ROE 1.25%  |  6.55%
F.Y. | Ann. Date 30-Sep-2019  |  20-Nov-2019

Annualized Result ( EPS: 15.00, P/E: 13.80 )

Revenue | NP to SH 2,806,462  |  39,172
RPS | P/RPS 1,074.33 Cent  |  0.19
EPS | P/E | EY 15.00 Cent  |  13.80  |  7.24%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -32.22%  |    -22.75%
NP Margin | ROE 1.39%  |  7.59%
F.Y. | Ann. Date 30-Sep-2019  |  20-Nov-2019



Business Performance

Business Performance (By Quarter)

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 1 / 4 25.00% 1 / 8 12.50%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 8 0.00%
Total Dividend Years 3 / 4 75.00% 7 / 8 88.00%
Continuous Quarters Of Dividend 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 4 0.00% 0 / 8 0.00%
Average ROE 1.62% 2.23%
Average Net Profit Margin 1.22% 1.86%

Business Performance (By Year)

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Years Of Revenue Growth 2 / 5 40.00% 2 / 10 20.00%
Total Positive Profit Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Positive Profit 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Profit Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Years Of Adjusted EPS Growth 0 / 5 0.00% 0 / 10 0.00%
Total Dividend Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Dividend 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Dividend Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Years Of Adjusted Dps Growth 0 / 5 0.00% 0 / 10 0.00%
Average ROE 12.17% 11.66%
Average Net Profit Margin 2.91% 3.14%

Key Result

Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 2,701,491 2,806,462 2,384,956 1,916,929 2,242,036
NP to SH 33,816 39,172 42,468 57,942 63,955
Dividend 27,347 29,557 41,621 45,080 56,510
Adjusted EPS 12.94 15.00 16.26 22.18 24.48
Adjusted DPS 10.47 11.31 15.93 17.26 21.63

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.


Growth

Growth (By Quarter)

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue 19.10% 21.98% 17.70% 6.14% 12.38%
NP to Owner -94.82% -96.80% -22.75% -94.31% -95.89%
Dividend 0.00% 0.00% -39.10% 0.00% 0.00%
Adj. EPS -94.82% -96.80% -22.75% -94.31% -95.89%
Adj. DPS 0.00% 0.00% -39.10% 0.00% 0.00%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

Growth (By Year)

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 16.25% 20.49% 40.93% 20.76% 25.17% 46.40% 6.16% 3.65% 21.23%
NP to Owner -37.17% -47.13% -41.64% -27.22% -38.75% -32.39% 18.04% -15.84% -7.11%
Dividend -44.54% -51.61% -39.34% - % - % - % 18.95% -12.73% 9.39%
Adj. EPS -37.17% -47.13% -41.64% -27.22% -38.75% -32.39% 18.04% -15.84% -7.11%
Adj. DPS -44.54% -51.61% -39.34% - % - % - % 18.95% -12.73% 9.39%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Analyze this stock with MQ Trader system
  2 people like this.
 
Wirajati Charges has no cash flow impact, like depreciations...worry? I am not, good opportunity to collect maybe my wish come true...rm2....or lower.
20/11/2019 2:29 PM
8888_ Who goreng dare admit? Beside Pharma which company announce today QR dare answer?
20/11/2019 2:45 PM
shawn88 yspsah is still strong....
20/11/2019 2:50 PM
memorylane thats the disadvantage of thin profit margin...
20/11/2019 2:59 PM
MCA_ Profit down 97% no limit down?
20/11/2019 3:00 PM
MCA_ 2.2 stubbornly you have answer? QR like non-event.

memorylane thats the disadvantage of thin profit margin...
20/11/2019 2:59 PM
20/11/2019 3:08 PM
RainT Roller coaster
20/11/2019 3:38 PM
Newplayer286 Drop so little
20/11/2019 3:39 PM
Sebastian Power monopoly also no profts margin? If open tender then just close shop better
20/11/2019 3:46 PM
patrick2 i afraid this non recurring charges is not time bis, may be there are some more in the future...anybody got any ideas how much more need to charge off??
20/11/2019 3:55 PM
Wirajati Because pharma charges lowest, think you can find another to compete, an entry barrier? Hihi, they already explain...the charges is on amortization of system (accounting treatment), there is more to come. This is a narrative i usually observe to tone down the sentiment. Like tm case, losses after impairment, but cash flow still good. And it climbs back some of the lost ground.You worry? I am not.
20/11/2019 4:04 PM
patrick2 yes, u are right, not affecting cash flow.. but more to come means profit affected in the coming time...and perhaps dividend also affected
20/11/2019 4:11 PM
patrick2 first, why need to amortise the system? is it due to no more concession as per previous contract??
20/11/2019 4:18 PM
Wirajati Dont worry there was never a single year without dividends even withsome lost quarters, this one just reduce accounting profit
20/11/2019 4:24 PM
patrick2 but u see this quarter aldy no more dividend..
20/11/2019 4:25 PM
Titan Meaning 4Q result will be worst than this? Company gives head up to investor???....good management.

"In the final quarter of the year, the Group foresee further impact on earnings due to higher amortization."
20/11/2019 4:25 PM
Wirajati Good. The game they played is to push one particular shareholder out (you know who).
20/11/2019 4:31 PM
Wirajati He sold, i bought
20/11/2019 4:35 PM
Titan push share holder out?....pls share coz i really dunno who. Thanks
20/11/2019 4:57 PM
Wirajati Najib's former man
20/11/2019 5:42 PM
noah There will be more amortizatuon coming as the PHIS system is a part of the concession contract.

So if the concession were to put under open tender, so do the PHIS system.

If the system can't perform then it will be subject to change if other vendor are able to offer a better system at an affordable price.

Try ask any PHIS system users in the gov sector their comment on this system..
20/11/2019 6:31 PM
pang72 My sifu Facebook live called buy...
If you buy, you trap... If you sell, you are smart!!
20/11/2019 7:11 PM
patrick2 to be exact, what is the balance of the amt need to further amortise??
20/11/2019 10:36 PM
JN88 pang72:if your sifu ask buy...then you buy morning sell at evening....
20/11/2019 11:18 PM
patrick2 actually when this PHIS started??
21/11/2019 11:38 AM
RainT Amortise is similar like deprection , the concept is the same . just the name is different

depreciation is for fixed assets, tangible assets (which we can see)

amortise is for software, system, rights that all this cannot be touch or see

so when PHARMA make a system , then start to use it, it need to be amortise throughout the period
is like this system also contribute to small part of the comapany sales
21/11/2019 2:20 PM
patrick2 u are right.....jz wondering how much more need to charge off??
21/11/2019 2:48 PM
stockmarket101 Is Pharmaniaga a recession-proof stock? TIA.
21/11/2019 7:08 PM
noah goodwill 131m,
software 18.5m,
rights to supply 209m

total amounting 400.9m

"The carrying amounts of goodwill allocated to the Group’s cash-generating units (“CGUs”)

The recoverable amounts of the CGUs are determined based on value-in-use (“VIU”) calculations. Cash flows are
derived from financial budgets approved by the Directors covering a range of five-year period to ten-year period that
reflects the product lifecycle. The projections reflect management’s expectation of sales volume growth and product
margins for the CGUs based on current assessment of market share and expectations of market growth and the
continuity of the concession agreement with the government."

The key assumptions used in the value-in-use calculations are set out below:
• Business analysis – The cash-generating unit makes assumptions about the demand for these new
products under development in the market place and the continuity of the concession agreement with the
government. These assumptions are used to drive the planning assumptions for sales volume taking into
consideration the projected timing for development, testing, registration and commercialisation using a
projected long-term average growth rate of 3% to 5% (2017: 3% to 5%) per annum.
• Discount rate – In measuring the recoverable amount based on the value-in-use calculations, discount rate
of 11.60% (2017: 9.46%) per annum has been applied. The discount rate reflects the prevailing market rate
applicable to the industry adjusted for the risk of the assets.
21/11/2019 7:47 PM
noah so you know what comes next in the event the concession agreement is not being renewed.
21/11/2019 7:49 PM
patrick2 from your analysis, so how much more amortisation need to be charge off??
22/11/2019 12:28 AM
noah ''Due to the shorter than expected contract period awarded to Pharmaniaga of only five-year, we estimate that the amortisation rate of PHIS will doubled to about RM10.0m quarterly and RM40.0m annually for the next five years from 4QFY19 onwards.''

Based on IB analyst.
22/11/2019 7:31 AM
patrick2 ok thanks...
22/11/2019 9:16 AM
patrick2 and profit is going to reduce another five million in the coming time
22/11/2019 9:18 AM
kalofarmako Now that govt is removing concession, its a smart move for Pharmaniaga to focus on diversifying
22/11/2019 11:10 AM
patrick2 wonder how to diversify?? venture into new bis??
22/11/2019 11:28 AM
5354_ Why 2019 no more Nov or Dec dividend?
24/11/2019 7:11 AM
david123 Be patience
25/11/2019 8:14 AM
e1zzz i think gov wont stop the tender as pharma major shareholder are boustead and kwap..
it will be like NAFAS when gov award direcly although open tender is call
25/11/2019 5:29 PM
kalofarmako https://klse.i3investor.com/blogs/MYpharmaceuticalnews/240245.jsp

PHARMANIAGA MAY STILL HAVE THE UPPER HAND
26/11/2019 2:42 PM
Daily9 EPF selling Boustead.
27/11/2019 4:17 AM
Yih Chyuan Khoo no news
27/11/2019 7:44 PM
bone It will go below 2
28/11/2019 11:01 AM
patrick2 what happens to pharma?? selling today
29/11/2019 3:05 PM
James Ng https://klse.i3investor.com/blogs/general/241983.jsp
[转贴] [PHARMANIAGA BHD:非经常性开支导致营业支出增加] - James的股票投资James Share Investing
30/11/2019 9:48 AM
AllanTingAS Waiting for below 2 to enter. No hurry
01/12/2019 10:42 AM
sengtong88 it seems like a double bottom
02/12/2019 9:02 PM
kalofarmako Pharmaniaga is contributing to non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) to support the registration of a new treatment for those with hepatitis C in Malaysia.

https://klse.i3investor.com/blogs/MYpharmaceuticalnews/242914.jsp
03/12/2019 9:15 AM
factorrumour lame.

dpharma is better.
03/12/2019 9:54 PM
Alex™ Wah.. This counter apa kes?
06/12/2019 4:15 PM